NAD+-Boosting Therapy Alleviates Nonalcoholic Fatty Liver Disease via Stimulating a Novel Exerkine Fndc5/Irisin

Objective

To investigate the effects of NAD-boosting therapy via NR on Fndc5/irisin levels in humans and its potential role in the development and progression of nonalcoholic fatty liver disease (NAFLD).

Study Design

General screening test with 6 healthy human subjects

Dose

1000 mg

Duration

2 weeks

Key Outcomes

  • NR supplementation increased plasma levels of Fndc5/irisin. A similar increase in plasma Fndc5/irisin was observed after two weeks of exercise, suggesting Fndc5/irisin may be a link between NAD+ and physical exercise.

Clinical, Liver HealthANAD Staff